Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SAL0137 Dose 1

Phase 2

SShenzhen Salubris Pharmaceuticals Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lipoprotein(a)Not yet recruiting

Lipoprotein(a)Phase 2

Not yet recruiting

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Lipoprotein(a)

NCT07729475

Clinical

Trials by Indication[1]

Lipoprotein(a)1 trial

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Oral SAL0137 Tablets in Adult Patients With Elevated Lipoprotein(a) and Increased Risk of Cardiovascular Events

Not yet recruiting·SShenzhen Salubris Pharmaceuticals Co., Ltd.·Phase 2·NCT07729475·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SAL0137 Dose 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for SAL0137 Dose 1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shenzhen Salubris Pharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SShenzhen Salubris Pharmaceuticals Co., Ltd.

Related News